Pacific Shuanglin Bio pharmacy Co Ltd (000403) - Total Liabilities
Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) has total liabilities worth CN¥1.28 Billion CNY (≈ $187.12 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 000403 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Pacific Shuanglin Bio pharmacy Co Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 000403 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Total Liabilities
The table below lists competitors of Pacific Shuanglin Bio pharmacy Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alimak Hek Group AB
ST:ALIG
|
Sweden | Skr6.23 Billion |
|
Rusta AB (publ)
ST:RUSTA
|
Sweden | Skr7.45 Billion |
|
Tabcorp Holdings Ltd
AU:TAH
|
Australia | AU$1.87 Billion |
|
TGS ASA SP.ADR/1
F:TGC0
|
Germany | €1.95 Billion |
|
Supreme Petrochem Limited
NSE:SPLPETRO
|
India | Rs11.12 Billion |
|
Black Box Limited
NSE:BBOX
|
India | Rs26.34 Billion |
|
Shenzhen Jufei Optoelectronics
SHE:300303
|
China | CN¥2.53 Billion |
|
Suzhou Gold Mantis Construction Decoration Co Ltd
SHE:002081
|
China | CN¥17.14 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Pacific Shuanglin Bio pharmacy Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Pacific Shuanglin Bio pharmacy Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacific Shuanglin Bio pharmacy Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacific Shuanglin Bio pharmacy Co Ltd (1993–2025)
The table below shows the annual total liabilities of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.39 Billion ≈ $202.68 Million |
+4.24% |
| 2024-12-31 | CN¥1.33 Billion ≈ $194.44 Million |
+9.94% |
| 2023-12-31 | CN¥1.21 Billion ≈ $176.86 Million |
+7.80% |
| 2022-12-31 | CN¥1.12 Billion ≈ $164.07 Million |
+47.51% |
| 2021-12-31 | CN¥760.07 Million ≈ $111.22 Million |
+10.84% |
| 2020-12-31 | CN¥685.71 Million ≈ $100.34 Million |
+45.88% |
| 2019-12-31 | CN¥470.04 Million ≈ $68.78 Million |
-32.67% |
| 2018-12-31 | CN¥698.08 Million ≈ $102.15 Million |
-8.35% |
| 2017-12-31 | CN¥761.70 Million ≈ $111.46 Million |
+9.38% |
| 2016-12-31 | CN¥696.41 Million ≈ $101.91 Million |
-5.87% |
| 2015-12-31 | CN¥739.82 Million ≈ $108.26 Million |
+0.63% |
| 2014-12-31 | CN¥735.16 Million ≈ $107.58 Million |
-12.01% |
| 2013-12-31 | CN¥835.47 Million ≈ $122.26 Million |
+7.08% |
| 2012-12-31 | CN¥780.27 Million ≈ $114.18 Million |
+15.07% |
| 2011-12-31 | CN¥678.06 Million ≈ $99.22 Million |
+4.09% |
| 2010-12-31 | CN¥651.42 Million ≈ $95.32 Million |
-41.53% |
| 2009-12-31 | CN¥1.11 Billion ≈ $163.04 Million |
+7.39% |
| 2008-12-31 | CN¥1.04 Billion ≈ $151.82 Million |
-37.10% |
| 2007-12-31 | CN¥1.65 Billion ≈ $241.38 Million |
-4.79% |
| 2006-12-31 | CN¥1.73 Billion ≈ $253.54 Million |
-12.05% |
| 2005-12-31 | CN¥1.97 Billion ≈ $288.28 Million |
+30.17% |
| 2004-12-31 | CN¥1.51 Billion ≈ $221.47 Million |
+8.05% |
| 2003-12-31 | CN¥1.40 Billion ≈ $204.97 Million |
+82.97% |
| 2002-12-31 | CN¥765.52 Million ≈ $112.02 Million |
+10.81% |
| 2001-12-31 | CN¥690.82 Million ≈ $101.09 Million |
+19.25% |
| 2000-12-31 | CN¥579.29 Million ≈ $84.77 Million |
+20.96% |
| 1999-12-31 | CN¥478.92 Million ≈ $70.08 Million |
+66.13% |
| 1998-12-31 | CN¥288.28 Million ≈ $42.18 Million |
+50.00% |
| 1997-12-31 | CN¥192.19 Million ≈ $28.12 Million |
+9.41% |
| 1996-12-31 | CN¥175.67 Million ≈ $25.71 Million |
+30.05% |
| 1995-12-31 | CN¥135.07 Million ≈ $19.77 Million |
+0.79% |
| 1994-12-31 | CN¥134.01 Million ≈ $19.61 Million |
-0.48% |
| 1993-12-31 | CN¥134.65 Million ≈ $19.70 Million |
-- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more